The Full Wiki

More info on alprazolam

alprazolam: Wikis


Systematic (IUPAC) name
CAS number 28981-97-7
ATC code N05BA12
PubChem 2118
DrugBank APRD00280
ChemSpider 2034
Chemical data
Formula C17H13ClN4 
Mol. mass 308.765
Pharmacokinetic data
Bioavailability 80–90%
Metabolism Hepatic, via Cytochrome P450 3A4
Half life Immediate release: 11.2 hours;[1] Extended release: 10.7–15.8 hours[2]
Excretion Renal
Therapeutic considerations
Pregnancy cat.


Legal status

Class C(UK) Schedule IV(US)

Routes Oral

Alprazolam, also known under the trade names Xanax, Xanor and Niravam, is a short-acting drug of the benzodiazepine class used to treat moderate to severe anxiety disorders, panic attacks, and is used as an adjunctive treatment for anxiety associated with moderate depression. It is also available in an extended-release form, Xanax XR, both of which are now available in generic form. Alprazolam possesses anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant properties.[3]

Alprazolam may be habit-forming, and long-term use and abuse may cause a physical dependence to develop along with withdrawal reactions during abrupt or rapid discontinuation. In the USA, alprazolam is a schedule IV controlled substance under the Controlled Substances Act.[4]



Alprazolam was first synthesized by Upjohn (now a part of Pfizer). It is covered under U.S. Patent 3,987,052, which was filed on October 29, 1969, granted on October 19, 1976 and expired in September 1993. Alprazolam was released in 1981.[5][6] The first approved indication was panic disorder. Upjohn took this direction at the behest of a young psychiatrist David Sheehan. Sheehan's suggestion was to use the new distinction the DSM-III created in the classification of anxiety disorders between generalized anxiety disorder (GAD) and panic disorder in order to market alprazolam specifically for the latter. Panic disorder was, at that point, perceived to be rare and treatable only with tricyclic antidepressants; benzodiazepines were thought to be ineffective. However, from his clinical experience, Sheehan knew panic disorder to be both widespread among the populace and responsive to benzodiazepines. He suggested to Upjohn that marketing alprazolam for panic disorder would both cover new diagnostic territory and emphasize the unique potency of this drug. Sheehan describes that the first group of patients treated by alprazolam was so impressed by its action that they knew outright — this drug was going to be a hit. A few of those patients actually pooled their money and purchased stock in Upjohn. Several months later, when alprazolam was approved by the United States Food and Drug Administration, they sold out and made a profit.[7]

Alprazolam has an exceptional history insofar as soon after its introduction a large number of case reports were published in the medical literature of severe withdrawal symptom-related case reports of psychoses, seizures, and intense rebound anxiety upon discontinuation of alprazolam.[8]


The main medical uses for alprazolam include:

Panic disorder

Alprazolam is FDA-approved for the short-term treatment (up to 8 weeks) of panic disorder, with or without agoraphobia. Alprazolam is very effective in treating moderate to severe anxiety, essential tremor, and panic attacks. Physicians that elect to prescribe alprazolam for longer than 8 weeks should be aware that continued efficacy has not been systematically demonstrated beyond 8 weeks' use, as tolerance to alprazolam's effects may occur after 8 weeks and necessitate discontinuation or physician-directed dose escalation.[9] However, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient.[10]

Anxiety disorder

Alprazolam is indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual DSM-III-R diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety.[10] Alprazolam is recommended for the short-term treatment (2–4 weeks) of severe acute anxiety. Alprazolam should only very rarely be used for longer periods of time – the body becomes rapidly tolerant to the drug's effects, which may translate to decreased efficacy.[11][12]

Alprazolam is sometimes prescribed for anxiety with associated depression. There is some evidence for antidepressant treatment of clinical depression in outpatient settings; evidence for inpatients is lacking.[13] The antidepressant effects of alprazolam may be due to its effects on beta-adrenergic receptors.[14] Other benzodiazepines are not known to have antidepressant activity.[15][16] Studies show that any antidepressant action of alprazolam is questionable and generally weak in comparison to those of antidepressant medications.[17][18][19][20] In contrast, while alprazolam in acute or short-term treatment may have some antidepressant properties, there is evidence that up to a third of long-term users of alprazolam may develop depression.[21]


File:Side effects of
Main side effects of alprazolam.[22] More serious effects motivate immediate contact with health care provider.[22]

Although the side-effect profile of alprazolam is, in general, benign, side-effects may occur in some patients and are more likely the higher the dosage taken. Some side-effects may disappear with continued treatment. If signs of an allergic reaction occur - such as hives; difficulty breathing; swelling of face, lips, tongue, or throat - medical attention should be sought immediately. Medical attention should also be sought immediately if signs of jaundice appear: yellowing of the skin or eyes. Other side-effects that may occur are as follows:

Paradoxical Reactions

Although unusual, if the following paradoxical reactions occur, the prescribing physician or other healthcare professional should be alerted and the medication gradually discontinued:

Physical dependence and withdrawal

Alprazolam, like other benzodiazepines, binds to specific sites on the GABAA gamma-amino-butyric acid receptor. When bound to these sites, which are referred to as benzodiazepine receptors, it modulates the effect of GABA A receptors and, thus, GABAnergic neurons. Long-term use causes adaptive changes in the benzodiazepine receptors, making them less sensitive to stimulation and less powerful in their effects.[44]

Not all withdrawal effects are evidence of true dependence or withdrawal. Recurrence of symptoms such as anxiety may simply indicate that the drug was having its expected anti-anxiety effect and that, in the absence of the drug, the symptom has returned to pretreatment levels. If the symptoms are more severe or frequent, the patient may be experiencing a rebound effect due to the removal of the drug. Either of these can occur without the patient's actually being drug-dependent.[44]

Alprazolam and other benzodiazepines may also cause the development of physical dependence, tolerance, and benzodiazepine withdrawal symptoms during rapid dose reduction or cessation of therapy after long-term treatment.[45][46] There is a higher chance of withdrawal reactions if the drug is administered in a higher dosage than recommended, or if a patient stops taking the medication altogether without slowly allowing the body to adjust to a lower-dosage regimen.[47][48][49]

In 1992, Romach and colleagues reported that dose escalation is not a characteristic of long-term alprazolam users, and the majority of patients indicated that alprazolam continued to be effective, suggesting that tolerance to the anti-anxiety effect is limited.[50]

If a patient feels the need to end treatment with alprazolam, he/she should consult his/her physician before discontinuing the medication. Some common symptoms of alprazolam discontinuation include tachycardia, dysphoria, dry mouth, loss of appetite, insomnia, anxiety, dizziness, tremors, nausea, cramps, vomiting, diarrhea, panic attacks, mood swings, heart palpitations, memory loss. Less common and more severe reactions can occur, including hallucinations, seizures or fever[51]

Patients taking a dosing regimen larger than 4 mg per day have an increased potential for dependence. This medication may cause withdrawal symptoms upon abrupt withdrawal or rapid tapering, which in some cases have been known to cause seizures. The discontinuation of this medication may also cause a reaction called rebound anxiety. Other withdrawal effects reported from discontinuing alprazolam therapy include homicidal ideation (very rare), rage reactions, hyperalertness, vivid dreams, and intrusive thoughts.[52] Grand mal seizures have occurred after abrupt withdrawal after only short-term use. Therefore, even short-term users of alprazolam should taper off of their medication slowly to avoid serious withdrawal reactions including seizures.[53][54]

Alprazolam should never be abruptly stopped if taken regularly for any length of time because severe withdrawal symptoms may occur. Severe psychosis and seizures have been reported in the medical literature from abrupt alprazolam discontinuation,[55][56] and one death occurred from withdrawal-related seizures after gradual dose reduction.[56]

In a 1983 study of patients that had taken long-acting benzodiazepines, e.g., clorazepate, for extended periods, the medications were stopped abruptly under double-blind conditions (that is, patients were receiving either placebo or the same drug they had been taking). Only 5% of patients that had been taking the drug for less than 8 months demonstrated withdrawal symptoms, but 43% of those that had been taking them for more than 8 months did, whereas, with alprazolam - a short-acting benzodiazepine - taken for 8 weeks, 35% of patients experienced significant rebound anxiety. To some degree, these older benzodiazepines are self-tapering.[57]

The benzodiazepines diazepam (Valium) and oxazepam (Serepax) have been found to produce fewer withdrawal reactions than alprazolam (Xanax) or lorazepam (Temesta/Ativan). Factors that determine the risk of psychological dependence or physical dependence and the severity of the benzodiazepine withdrawal symptoms experienced during dose reduction of alprazolam include: dosage used, length of use, frequency of dosing, personality characteristics of the individual, previous use of cross-dependent/cross-tolerant drugs (alcohol or other sedative-hypnotic drugs), current use of cross-dependent/cross-tolerant drugs (alcohol or other sedative-hypnotic drugs), use of other short-acting, high-potency benzodiazepines[8][58] and method of discontinuation.[59]


Use of alprazolam should be avoided, carefully monitored by medical professionals, in individuals with the following conditions: Myasthenia gravis, acute narrow-angle glaucoma, severe liver deficiencies (e.g., cirrhosis), severe sleep apnea, pre-existing respiratory depression, marked neuromuscular respiratory weakness including unstable myasthenia gravis, acute pulmonary insufficiency, chronic psychosis, hypersensitivity or allergy to alprazolam or other drugs in the benzodiazepine class, borderline personality disorder (may induce suicidality and dyscontrol).[60][61][62][63]

Women who are pregnant or are planning on becoming pregnant should avoid starting alprazolam.[64] It should be considered that the child born of a mother receiving benzodiazepines may be at risk of developing withdrawal reactions during the postnatal period. Also, neonatal flaccidity and respiratory problems have been reported in children born of mothers that have been receiving benzodiazepines.[65]

Benzodiazepines, including alprazolam, are known to be excreted in human milk.[66] Chronic administration of diazepam to nursing mothers has been reported to cause their infants to become lethargic and to lose weight.[67][68] As a general rule, nursing should not be undertaken by mothers who use alprazolam.

Elderly individuals should be cautious in the use of alprazolam due to the possibility of increased susceptibility to side-effects, especially loss of coordination and drowsiness.[68]

Like all central nervous system depressants, including alcohol, alprazolam in larger-than-normal doses can cause significant deterioration in alertness, combined with increased feelings of drowsiness, especially in those unaccustomed to the drug's effects.[69] People driving or conducting activities that require vigilance should exercise caution in using alprazolam or any other depressant.


Alprazolam is classed as a high-potency benzodiazepine and is a triazolobenzodiazepine,[70][71] that is, a benzodiazepine with a triazole ring attached to its structure. Benzodiazepines produce a variety of therapeutic and adverse effects by binding to the benzodiazepine site on the GABAA receptor and modulating the function of the GABA receptor, the most prolific inhibitory receptor within the brain. The GABA chemical and receptor system produces inhibitory or calming effects of alprazolam on the nervous system. The GABAA receptor is made up from 5 subunits out of a possible 19, and GABAA receptors made up of different combinations of subunits have different properties, different locations within the brain, and, what is significant, different activities with regard to benzodiazepines.[33][72]


Alprazolam is readily absorbed from the gastrointestinal tract with a bioavailability of 80–100%. The peak plasma concentration is achieved in 1–2 hours. Most of the drug is bound to plasma protein, mainly serum albumin. Alprazolam is hydroxylated in the liver to α-hydroxyalprazolam, which is also pharmacologically active but much less so than the parent compound. This and other metabolites are later excreted in urine as glucuronides. Some of the drug is also excreted in unchanged form. The elderly clear alprazolam more slowly than younger adults.[73]

Food and drug interactions

Cimetidine, erythromycin, fluoxetine, fluvoxamine, itraconazole, ketoconazole, nefazodone, propoxyphene, and ritonavir all interact with alprazolam leading to a delayed clearance of alprazolam, which may result in excessive accumulation of alprazolam. This may result in excessive sedation and other adverse effects associated with excessive intake of alprazolam.[73][74]

Imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.[75] Oral contraceptive pills reduce the clearance of alprazolam, which may lead to increased plasma levels of alprazolam and accumulation.[76]

Alcohol is one of the most important and common interactions. Alcohol and benzodiazepines such as alprazolam taken in combination have a synergistic effect on one another, which can cause severe sedation, behavioral changes, and intoxication. The more alcohol and alprazolam taken the worse the interaction.[77]

Recreational use

generic 2mg alprazolam tablets.]]

Alprazolam has a relatively high potential for recreational use.[78] Injection of alprazolam, though extremely rare, is considered especially dangerous by medical professionals[79] because, when crushed in water it will not fully dissolve (40 µg/ml of H2O at pH 7, and 12 mg/mL at pH 1.2[80]), potentially causing severe damage to arteries if not filtered properly. While it is somewhat soluble in alcohol, the combination of the two, particularly when injected, has the potential to cause a serious, and potentially fatal, overdose. Alprazolam may also be insufflated.[81] However, long-term use of benzodiazepines does not usually result in notable dose escalation, and most prescribed alprazolam users do not use their medication recreationally.[82]

Alprazolam is sometimes used with other recreational drugs to relieve the panic or distress of dysphoric reactions to psychedelics such as LSD, and also to promote sleep in the "come-down" period following use of recreational drugs with stimulant or insomniac properties (such as LSD, cocaine, amphetamines, DXM, and MDMA, along with the related amphetamines). It is also often used in conjunction with marijuana or heroin to potentiate the relaxing effect.[83][84][85][86][87]

A large-scale nationwide USA government study conducted by SAMHSA found that, in the USA, benzodiazepines are, recreationally, the most frequently-used pharmaceutical, with 35% of drug-related visits to the Emergency Department involving benzodiazepines. Benzodiazepines are more commonly used recreationally than opiate pharmaceuticals, which accounted for 32% of visits to the emergency department. No other pharmaceutical is more commonly used recreationally than benzodiazepines; however, benzodiazepines remain in Schedule IV of the Controlled Substances Act, whereas opiates are much more strictly scheduled. Men use benzodiazepines recreationally as commonly as women. The report found that alprazolam is the most common benzodiazepine for recreational use followed by clonazepam, lorazepam, and diazepam.[4] Those who have used other drugs for leisure are particularly likely to use alprazolam recreationally.

Patients at a high risk for misuse and addiction

At a particularly high risk for misuse and dependence are patients with a history of alcoholism (including a family history of alcoholism) or drug abuse and/or dependence[88][89][90][91][92] and patients with borderline personality disorder are at increased risk of misusing alprazolam.[93]


Overdoses of alprazolam can be mild to severe depending on how much of the drug is taken and if any other depressants have been taken. Alprazolam is significantly more toxic in overdose than other benzodiazepines with higher rates of fatalities. A study in New Zealand found that alprazolam is almost 8 times more likely to result in death in overdose than other sedative hypnotics as a group, with higher rates of ICU admissions and mechanical ventilation. Combined overdose with tricyclic antidepressants, alcohol, or opiates, or overdoses of alprazolam in the elderly, significantly increases the likelihood for severe toxicity and possible fatality.[94] Alprazolam (Xanax) overdose reflect the central nervous system depression of the brain and may include one or more of the following symptoms:[29]

About 50% of the cases of death involving alprazolam were attributed to combined drug toxicity of alprazolam and another drug, most often cocaine and methadone. Only 1% of such deaths was attributed to alprazolam alone.[95][96]


Alprazolam IR is available in 0.25 mg, 0.5 mg, 1 mg and 2 mg strength oral, orally disintegrating tablets.[97] Alprazolam Extended Release is available in 0.5 mg, 1 mg and 2 mg 3 mg strength oral

Alprazolam is available in English-speaking countries under the following brand names:

Brand Names[98]
Alganax, Alzolam, Alprax, Alprox, Alzam, Anxirid, Apo-Alpraz, Alzolam, Azor, Calmax, Gerax, Helex, Kalma, Nervin, Niravam, Novo-Alprazol, Nu-Alpraz, Tafil, Texidep, Xanax, Xanor, Zopax

Legal status

In the United States, alprazolam is a prescription drug and is assigned to Schedule IV of the Controlled Substances Act by the Drug Enforcement Administration.[99] Under the UK drug misuse classification system benzodiazepines are class C drugs.[100] Internationally, alprazolam is included under the United Nations Convention on Psychotropic Substances as Schedule IV.[101]

See also


  1. First DataBank (July 2008). "Xanax (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. 
  2. First DataBank (July 2008). "Xanax XR (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. 
  3. Mandrioli R, Mercolini L, Raggi MA (October 2008). "Benzodiazepine metabolism: an analytical perspective". Curr. Drug Metab. 9 (8): 827–44. doi:10.2174/138920008786049258. PMID 18855614. 
  4. 4.0 4.1 United States Government; U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2006). "Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits". Substance Abuse and Mental Health Services Administration. Retrieved on 9 February 2009. 
  5. Cynthia Cotts (November 19, 2007). "Xanax junkies". Boston, USA: The Phoenix. 
  6. 1981 American Journal of Psychiatry contains advertisements for Xanax as an available drug.
  7. Healy, David (2000). The Psychopharmacologists, Vol. III: Interviews. London: Arnold. pp. 479–504. ISBN 0-340-761105. 
  8. 8.0 8.1 Wolf B, Griffiths RR (December 1991). "Physical dependence on benzodiazepines: differences within the class". Drug Alcohol Depend 29 (2): 153–6. doi:10.1016/0376-8716(91)90044-Y. PMID 1686752. 
  9. FDA (23rd). "FDA APPROVED LABELING FOR XANAX XR" (pdf). Federal Drug Administration. 4. Retrieved on 2 August 2007. "The longer-term efficacy of XANAX XR has not been systematically evaluated. Thus, the physician that elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient." 
  10. 10.0 10.1 First DataBank (July 2008). "Xanax (Alprazolam) clinical pharmacology - prescription drugs and medications at RxList". RxList. 
  11. NetDoctor (October 1, 2006). "Xanax". Retrieved on 2 August 2007. 
  12. The British National Formulary (2007). "Alprazolam". BNF. Retrieved on 2 August 2007. 
  13. Warner MD; Peabody CA, Whiteford HA, Hollister LE (April 1988). "Alprazolam as an antidepressant". J Clin Psychiatry 49 (4): 148–50. PMID 3281931. 
  14. Sethy, Vh; Hodges, Dh, Jr (May 1982). "Role of beta-adrenergic receptors in the antidepressant activity of alprazolam.". Research communications in chemical pathology and pharmacology 36 (2): 329–32. PMID 6285432. 
  15. Lader, Mh (09 Dec 1985). "Treatment of affective disorders." (Free full text). British journal of clinical pharmacology 19 (Suppl 1): 29S–30S. PMID 2859875. 
  16. Johnson, Da (09 Dec 1985). "The use of benzodiazepines in depression." (Free full text). British journal of clinical pharmacology 19 (Suppl 1): 31S–35S. PMID 2859876. 
  17. Kostowski W, Malatyńska E, Płaźnik A, Dyr W, Danysz W (1986). "Comparative studies on antidepressant action of alprazolam in different animal models". Pol J Pharmacol Pharm 38 (5-6): 471–81. PMID 2883637. 
  18. Srisurapanont, M; Boonyanaruthee, V (Mar 1997). "Alprazolam and standard antidepressants in the treatment of depression: a meta-analysis of the antidepressant effect.". Journal of the Medical Association of Thailand = Chotmaihet thangphaet 80 (3): 183–8. PMID 9175386. 
  19. Brasfield, Kh (Sep 1991). "Practical psychopharmacologic considerations in depression.". The Nursing clinics of North America 26 (3): 651–63. PMID 1891399. 
  20. Hubain, Pp; Castro, P; Mesters, P; De, Maertelaer, V; Mendlewicz, J (Jan 1990). "Alprazolam and amitriptyline in the treatment of major depressive disorder: a double-blind clinical and sleep EEG study.". Journal of affective disorders 18 (1): 67–73. doi:10.1016/0165-0327(90)90118-R. PMID 2136871. 
  21. Lydiard, Rb; Laraia, Mt; Ballenger, Jc; Howell, Ef (May 1987). "Emergence of depressive symptoms in patients receiving alprazolam for panic disorder.". The American journal of psychiatry 144 (5): 664–5. PMID 3578580. 
  22. 22.0 22.1 MedlinePlus --> Alprazolam The American Society of Health-System Pharmacist. Last Reviewed - 09/01/2008
  23. Zawertailo LA, Busto U, Kaplan HL, Sellers EM (April 1995). "Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans". J Clin Psychopharmacol 15 (2): 117–24. doi:10.1097/00004714-199504000-00007. PMID 7782484. 
  24. 24.0 24.1 Rawson NS, Rawson MJ (1999). "Acute adverse event signalling scheme using the Saskatchewan Administrative health care utilization datafiles: results for two benzodiazepines". Can J Clin Pharmacol 6 (3): 159–66. PMID 10495368. 
  25. 25.0 25.1 "Alprazolam – Complete medical information regarding this treatment of anxiety disorders on". Retrieved on 2 August 2007. 
  26. Michel L, Lang JP (2003). "[Benzodiazepines and forensic aspects]" (in French). Encephale 29 (6): 479–85. PMID 15029082. 
  27. Kravitz HM, Fawcett J, Newman AJ (October 1993). "Alprazolam and depression: a review of risks and benefits". J Clin Psychiatry 54 (Suppl): 78–84; discussion 85. PMID 8262892. 
  28. Hori A (February 1998). "Pharmacotherapy for personality disorders". Psychiatry Clin. Neurosci. 52 (1): 13–9. doi:10.1111/j.1440-1819.1998.tb00967.x. PMID 9682928. 
  29. 29.0 29.1 "alprazolam Side Effects, Interactions and Information -". Retrieved on 2 August 2007. 
  30. "Complete Alprazolam information from". Retrieved on 2 August 2007. 
  31. Cassano GB, Toni C, Petracca A, et al. (March 1994). "Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo". Eur Neuropsychopharmacol 4 (1): 47–53. doi:10.1016/0924-977X(94)90314-X. PMID 8204996. 
  32. Münte TF, Gehde E, Johannes S, Seewald M, Heinze HJ (1996). "Effects of alprazolam and bromazepam on visual search and verbal recognition memory in humans: a study with event-related brain potentials". Neuropsychobiology 34 (1): 49–56. doi:10.1159/000119291. PMID 8884760. 
  33. 33.0 33.1 Barbee, Jg (Oct 1993). "Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives.". The Journal of clinical psychiatry 54 (Suppl): 86–97; discussion 98–101. PMID 8262893. 
  34. "ALPRAZOLAM - ORAL (Xanax) side effects, medical uses, and drug interactions.". Retrieved on 2 August 2007. 
  35. Elie R, Lamontagne Y (June 1984). "Alprazolam and diazepam in the treatment of generalized anxiety". J Clin Psychopharmacol 4 (3): 125–9. doi:10.1097/00004714-198406000-00002. PMID 6145726. 
  36. Evans SM, Foltin RW, Fischman MW (June 1999). "Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder". Appetite 32 (3): 331–49. doi:10.1006/appe.1998.0222. PMID 10336792. 
  37. Noyes R, DuPont RL, Pecknold JC, et al. (May 1988). "Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety". Arch. Gen. Psychiatry 45 (5): 423–8. PMID 3358644. 
  38. Béchir M, Schwegler K, Chenevard R, et al. (July 2007). "Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders". Auton Neurosci 134 (1-2): 69–73. doi:10.1016/j.autneu.2007.01.007. PMID 17363337. 
  39. Rapaport, M; Braff, Dl (Jan 1985). "Alprazolam and hostility.". The American journal of psychiatry 142 (1): 146. PMID 2857070. 
  40. Michel L, Lang JP (2003). "[Benzodiazepines and forensic aspects]" (in French). Encephale 29 (6): 479–85. PMID 15029082. 
  41. Arana, Gw; Pearlman, C; Shader, Ri (Mar 1985). "Alprazolam-induced mania: two clinical cases.". The American journal of psychiatry 142 (3): 368–9. PMID 2857534. 
  42. Strahan A, Rosenthal J, Kaswan M, Winston A (July 1985). "Three case reports of acute paroxysmal excitement associated with alprazolam treatment". Am J Psychiatry 142 (7): 859–61. PMID 2861755. 
  43. Reddy J, Khanna S, Anand U, Banerjee A (August 1996). "Alprazolam-induced hypomania". Aust N Z J Psychiatry 30 (4): 550–2. doi:10.3109/00048679609065031. PMID 8887708. 
  44. 44.0 44.1 Stahl, Stephen (1996). Essential Pharmacology: Neuroscientific Basis and Practical Applications. Cambridge: Cambridge University Press. ISBN 0-521-42620-0. 
  45. Juergens, Sm; Morse, Rm (May 1988). "Alprazolam dependence in seven patients.". The American journal of psychiatry 145 (5): 625–7. PMID 3258735. 
  46. Klein, E (2002). "The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam.". The Journal of clinical psychiatry 63 (Suppl 14): 27–33. PMID 12562116. 
  47. Professor Heather Ashton (2002). "The Ashton Manual – Benzodiazepines: How They Work and How to Withdraw". Retrieved on 2008-10-31. 
  48. Dr JG McConnell (May 2007). "The Clinicopharmacotherapeutics of Benzodiazepine and Z drug dose Tapering Using Diazepam". bcnc. Retrieved on 2008-10-31. 
  49. Closser, Mh; Brower, Kj (Jul 1994). "Treatment of alprazolam withdrawal with chlordiazepoxide substitution and taper.". Journal of substance abuse treatment 11 (4): 319–23. doi:10.1016/0740-5472(94)90042-6. PMID 7966502. 
  50. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM (October 1992). "Characteristics of long-term alprazolam users in the community". J Clin Psychopharmacol 12 (5): 316–21. doi:10.1097/00004714-199210000-00004. PMID 1479048. 
  51. Fyer AJ; Liebowitz MR, Gorman JM, Campeas R, Levin A, Davies SO, Goetz D, Klein DF (March 1987). "Discontinuation of Alprazolam Treatment in Panic Patients". Am J Psychiatry ( 144 (3): 303–8. PMID 3826428. Retrieved on 10 December 2008. 
  52. Risse SC; Whitters A, Burke J, Chen S, Scurfield RM, Raskind MA. (1990). "Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder". The Journal of clinical psychiatry. 51 (5): 206–9. PMID 2335496. 
  53. Breier, A; Charney, Ds; Nelson, Jc (Dec 1984). "Seizures induced by abrupt discontinuation of alprazolam.". The American journal of psychiatry 141 (12): 1606–7. PMID 6150649. 
  54. Noyes R, Perry PJ, Crowe RR, et al. (January 1986). "Seizures following the withdrawal of alprazolam". J. Nerv. Ment. Dis. 174 (1): 50–2. doi:10.1097/00005053-198601000-00009. PMID 2867122. 
  55. Levy AB (1984). "Delirium and seizures due to abrupt alprazolam withdrawal: case report". J Clin Psychiatry 45 (1): 38–9. PMID 6141159. 
  56. 56.0 56.1 Haque W, Watson DJ, Bryant SG (1990). "Death following suspected alprazolam withdrawal seizures: a case report". Tex Med 86 (1): 44–7. PMID 2300914. 
  57. Schatzberg, Alan; DeBattista, Charles (2003). Manual of Clinical Psychopharmacology. Washington, DC: American Psychiatric Pub.. pp. 328–331. ISBN 1-58562-209-5. 
  58. Higgitt, A; Fonagy, P; Lader, M (1988). "The natural history of tolerance to the benzodiazepines.". Psychological medicine. Monograph supplement 13: 1–55. PMID 2908516. 
  59. Professor Heather Ashton (August 2002). "The Ashton Manual - Benzodiazepines: How They Work and How to Withdraw". 
  60. Hori A. (February 1998). "Pharmacotherapy for personality disorders". Psychiatry and clinical neurosciences. 52 (1): 13–9. doi:10.1111/j.1440-1819.1998.tb00967.x. PMID 9682928. 
  61. Gardner DL, Cowdry RW (January 1985). "Alprazolam-induced dyscontrol in borderline personality disorder". Am J Psychiatry 142 (1): 98–100. PMID 2857071. 
  62. "Alprazolam". British National Formulary. 2007. Retrieved on 3 August 2007. 
  63. (2007). "Alprazolam". Retrieved on 3 August 2007. 
  64. "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings at RxList". USA: July 2008. 4. 
  65. García-Algar O; López-Vílchez MA, Martín I, Mur A, Pellegrini M, Pacifici R, Rossi S, Pichini S. (2007). "Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis". Clinical toxicology (Philadelphia, Pa.). 45 (3): 295–8. PMID 17453885. 
  66. Oo CY; Kuhn RJ, Desai N, Wright CE, McNamara PJ. (September 1995). "Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk". British journal of clinical pharmacology. 40 (3): 231–6. PMID 8527284. 
  67. DataBank, Inc (July 2008). "Xanax (Alprazolam) Drug Information: Uses, Side Effects, Drug Interactions and Warnings at RxList". RxList. 8. Retrieved on 7 December 2008. 
  68. 68.0 68.1 "ALPRAZOLAM - ORAL (Xanax) side effects, medical uses, and drug interactions". MedicineNet. July 2005. Retrieved on 7 December 2008. 
  69. Kozená L; Frantik E, Horváth M. (May 1995). "Vigilance impairment after a single dose of benzodiazepines". Psychopharmacology (Berl). 119 (1): 39–45. doi:10.1007/BF02246052. PMID 7675948. 
  70. Skelton KH; Nemeroff CB, Owens MJ (October 20, 2004). "Spontaneous withdrawal from the triazolobenzodiazepine alprazolam increases cortical corticotropin-releasing factor mRNA expression". J Neurosci 24 (42): 9303–12. doi:10.1523/JNEUROSCI.1737-04.2004. PMID 15496666. 
  71. Chouinard G (2004). "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound". J Clin Psychiatry 65 (Suppl 5): 7–12. PMID 15078112. 
  72. White, G; Gurley, Da (Feb 1995). "Alpha subunits influence Zn block of gamma 2 containing GABAA receptor currents.". Neuroreport 6 (3): 461–4. doi:10.1097/00001756-199502000-00014. PMID 7766843. 
  73. 73.0 73.1 Greenblatt, Dj; Wright, Ce (Jun 1993). "Clinical pharmacokinetics of alprazolam. Therapeutic implications.". Clinical pharmacokinetics 24 (6): 453–71. doi:10.2165/00003088-199324060-00003. PMID 8513649. 
  74. Wang JS, DeVane CL (2003). "Pharmacokinetics and drug interactions of the sedative hypnotics" (PDF). Psychopharmacol Bull 37 (1): 10–29. PMID 14561946. 
  75. "FDA SPL Approved Application Filing for NDC Code 0228-3083 (Alprazolam by Actavis Elizabeth LLC)". AD535DF9-6361-460D-9648-450A0A6F61CD.xml. 
  76. Back DJ; Orme ML. (June 1990). "Pharmacokinetic drug interactions with oral contraceptives". Clin Pharmacokinet. 18 (6): 472–84. doi:10.2165/00003088-199018060-00004. PMID 2191822. 
  77. Michel L, Lang JP (2003). "[Benzodiazepines and forensic aspects]" (in French). Encephale 29 (6): 479–85. PMID 15029082. 
  78. Griffiths RR, Wolf B (August 1990). "Relative abuse liability of different benzodiazepines in drug abusers". J Clin Psychopharmacol 10 (4): 237–43. doi:10.1097/00004714-199008000-00002. PMID 1981067. 
  79. Eric C; Wang, Felix S, Chew. (2006). "MR Findings of Alprazolam Injection into the Femoral Artery with Microembolization and Rhabdomyolysis" (pdf). Radiology Case Reports 1 (3). 
  80. "DB00404 (Alprazolam)". Canada: DrugBank. August 26, 2008. 
  81. Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E (1991). "Snorting benzodiazepines". Am J Drug Alcohol Abuse 17 (4): 457–68. doi:10.3109/00952999109001605. PMID 1684083. 
  82. Soumerai SB, Simoni-Wastila L, Singer C, et al. (July 2003). "Lack of relationship between long-term use of benzodiazepines and escalation to high dosages". Psychiatr Serv 54 (7): 1006–11. doi:10.1176/ PMID 12851438. 
  83. Walker, Bm; Ettenberg, A (Apr 2003). "The effects of alprazolam on conditioned place preferences produced by intravenous heroin.". Pharmacology, biochemistry, and behavior 75 (1): 75–80. doi:10.1016/S0091-3057(03)00043-1. PMID 12759115. 
  84. MARCIA LANE (29 September 2006). "Xanax, alcohol mix kills 2". USA: St. Augustine Record. Retrieved on 10 December 2008. 
  85. Wright State University and the University of Akron (January 2008). "OSAM - O- GRAM Highlights of Statewide Drug Use Trends" (PDF). USA: Ohio Government. Retrieved on 10 December 2008. 
  87. "SURVEILLANCE OF DRUG ABUSE TRENDS IN THE STATE OF OHIO - A Report Prepared for the Ohio Department of Alcohol and Drug Addiction Services". USA: The Ohio Substance Abuse Monitoring Network. 31 July 2001. Retrieved on 10 December 2008. 
  88. Ballenger, Jc (Dec 1984). "Psychopharmacology of the anxiety disorders.". The Psychiatric clinics of North America 7 (4): 757–71. PMID 6151647. 
  89. Evans, Sm; Levin, Fr; Fischman, Mw (Jun 2000). "Increased sensitivity to alprazolam in females with a paternal history of alcoholism.". Psychopharmacology 150 (2): 150–62. doi:10.1007/s002130000421. PMID 10907668. 
  90. Streeter, Cc; Ciraulo, Da; Harris, Gj; Kaufman, Mj; Lewis, Rf; Knapp, Cm; Ciraulo, Am; Maas, Lc; Ungeheuer, M; Szulewski, S; Renshaw, Pf (May 1998). "Functional magnetic resonance imaging of alprazolam-induced changes in humans with familial alcoholism.". Psychiatry research 82 (2): 69–82. doi:10.1016/S0925-4927(98)00009-2. PMID 9754450. 
  91. Ciraulo, Da; Sarid-Segal, O; Knapp, C; Ciraulo, Am; Greenblatt, Dj; Shader, Ri (Jul 1996). "Liability to alprazolam abuse in daughters of alcoholics.". The American journal of psychiatry 153 (7): 956–8. PMID 8659624. 
  92. Ciraulo, Da; Barnhill, Jg; Greenblatt, Dj; Shader, Ri; Ciraulo, Am; Tarmey, Mf; Molloy, Ma; Foti, Me (Sep 1988). "Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men.". The Journal of clinical psychiatry 49 (9): 333–7. PMID 3417618. 
  93. Vorma, H; Naukkarinen, Hh; Sarna, Sj; Kuoppasalmi, Ki (2005). "Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence.". Substance use & misuse 40 (4): 499–510. doi:10.1081/JA-200052433. PMID 15830732. 
  94. Isbister GK, O'Regan L, Sibbritt D, Whyte IM (July 2004). "Alprazolam is relatively more toxic than other benzodiazepines in overdose". Br J Clin Pharmacol 58 (1): 88–95. doi:10.1111/j.1365-2125.2004.02089.x. PMID 15206998. 
  95. Wolf BC, Lavezzi WA, Sullivan LM, Middleberg RA, Flannagan LM (2005). "Alprazolam-related deaths in Palm Beach County". Am J Forensic Med Pathol 26 (1): 24–7. doi:10.1097/01.paf.0000153994.95642.c1. PMID 15725773. 
  96. Rogers, Wo; Hall, Ma; Brissie, Rm; Robinson, Ca (Jan 1997). "Detection of alprazolam in three cases of methadone/benzodiazepine overdose.". Journal of forensic sciences 42 (1): 155–6. PMID 8988593. 
  97. Merck Manual; Davis-Drug-Guide (5 February 2009). "alprazolam". Unbound Medicine. Retrieved on 10 March 2009. 
  98. "Benzodiazepine Names". Retrieved on 2008-10-31. 
  99. "DEA, Drug Scheduling" (in English). DEA. Retrieved on 2008-10-31. 
  100. UK Gov (1991). "Misuse of Drugs Act 1971 (c. 38)". The UK Statute Law database. 
  101. International Narcotics Control Board (August 2003). "List of psychotropic substances under international control" (PDF). Retrieved on 7 December 2008. 


Up to date as of January 15, 2010

Definition from Wiktionary, a free dictionary



Molecular structure of alprazolam




alprazolam (uncountable)

  1. (medicine) A specific antianxiety drug having the chemical formula C17H13ClN4
    • 2008 February 7, James Barron, “Medical Examiner Rules Ledger’s Death Accidental”, New York Times:
      Also in Mr. Ledger’s system were three anti-anxiety medications: diazepam, the generic name for Valium; alprazolam, commonly known as Xanax; and temazepam [] .


  • xanax, Xanax


Citable sentences

Up to date as of December 14, 2010

Here are sentences from other pages on Alprazolam, which are similar to those in the above article.

Got something to say? Make a comment.
Your name
Your email address